Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +49.89%
#2 PondCoin PondCoin +44.42%
#3 Pons Pons +42.05%
#4 TENDIES TENDIES +32.73%
#5 Purr Purr +31.46%
#6 StonkBroker StonkBroker +30.17%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +29.85%
#8 Magma Finance Magma Finance +28.34%
#9 Starpower Starpower +27.30%
#10 Ocean Protocol Ocean Protocol +26.90%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Provectus Biopharmaceuticals, Inc. Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc.

PVCT
Clasificación en acciones #28895
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm... Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to pioneering immunotherapy treatments. These therapies are grounded in its proprietary halogenated xanthene platform. Among its key developments is PV-10, an experimental autolytic cancer immunotherapy. This treatment is being explored for a range of adult solid tumor malignancies, encompassing melanoma and various gastrointestinal cancers (such as hepatocellular carcinoma, metastatic colorectal cancer to the liver, metastatic neuroendocrine tumors to the liver, and metastatic uveal melanoma to the liver). It also targets pediatric solid tumors, including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. Additionally, Provectus is advancing oral formulations of pharmaceutical-grade rose bengal sodium (cGMP RBS) to combat a broad spectrum of conditions. These include adult solid tumors (such as head and neck, breast, testicular, and colorectal cancers), pediatric blood cancers like leukemia, acute respiratory syndromes such as coronavirus, infections caused by multi-drug resistant bacteria (specifically Gram-negative bacteria), and certain ocular conditions, notably infectious keratitis. Furthermore, the company is progressing PH-10, an investigational immuno-dermatology agent designed to address inflammatory skin conditions like psoriasis and atopic dermatitis. Originally established in 2002, the company was initially named Provectus Pharmaceuticals, Inc., before rebranding as Provectus Biopharmaceuticals, Inc. in December 2013. Its operations are headquartered in Knoxville, Tennessee.
Precio por acción
$0.0573
Capitalización bursátil
$24.08M
Cambio (1 día)
0.53%
Cambio (1 año)
-28.55%
País
US
Comercio Provectus Biopharmaceuticals, Inc. (PVCT)

Categoría

Healthcare
Ratio P/E de Provectus Biopharmaceuticals, Inc. (PVCT)
Ratio P/E al 2026 TTM: 0
Según los últimos informes financieros y el precio de las acciones de Provectus Biopharmaceuticals, Inc., el P/E actual (TTM) de la empresa es 0. Al final de 2026, la empresa tenía un P/E de 0.
Historial del ratio P/E de Provectus Biopharmaceuticals, Inc. desde 2026 hasta 2026
Relación P/E al final de cada año
Año Ratio P/E Cambiar
Not enough data for the provided dates.
Relación P/E para empresas similares o competidores
Empresa P/E Ratio Diferencia del P/E Ratio País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
¿Cómo leer un P/E ratio?

El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.

Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.

Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.